JCEM:甲状腺切除的甲状腺癌患者发生2型糖尿病的风险增加

2021-11-02 MedSci原创 MedSci原创

接受甲状腺切除术的甲状腺癌患者比匹配的对照组更容易患2型糖尿病。左旋甲状腺素剂量与2型糖尿病风险之间存在U形剂量依赖性关系。

甲状腺切除术后甲状腺功能异常和随后的促甲状腺激素抑制会对甲状腺癌患者的血糖稳态产生不利影响。

近日,内分泌和代谢性疾病领域权威杂志Journal of Clinical Endocrinology & Metabolism上发表了一篇研究文章,该研究旨在调查甲状腺切除术是否会增加甲状腺癌患者患2型糖尿病的风险,并探讨左旋甲状腺素剂量与2型糖尿病风险之间的关联。

这项基于人群的回顾性队列研究,以韩国国民健康保险数据库为基础,研究人员纳入了2004年至2013年期间接受甲状腺切除术的36377名无糖尿病的甲状腺癌患者,并使用1:1倾向评分匹配非甲状腺癌受试者。该研究的主要结局指标为新发的2型糖尿病。

接受甲状腺切除术的甲状腺癌患者发生2型糖尿病的风险高于匹配的对照组(风险比[HR]为1.43,95%置信区间[CI]为1.39-1.47)。在甲状腺癌患者中,当左甲状腺素剂量处于第二个四分位数组(平均剂量为101-127μg/天)作为参考组时,左甲状腺素剂量处于第一个四分位数(<101μg/天)(HR为1.45,95%CI为1.36-1.54)和第四个四分位数组(≥150μg/天;HR为1.37,95%CI为1.29-1.45)的个体发生2型糖尿病的风险增加;同时,第三个四分位数组的风险降低(128-149μg/天;HR为0.91,95%CI为0.85-0.97)。

由此可见,接受甲状腺切除术的甲状腺癌患者比匹配的对照组更容易患2型糖尿病。左旋甲状腺素剂量与2型糖尿病风险之间存在U形剂量依赖性关系。

原始出处:

Eun Roh.et al.Increased risk of type 2 diabetes in patients with thyroid cancer after thyroidectomy: A nationwide cohort study.JCEM.2021.https://doi.org/10.1210/clinem/dgab776

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2063532, encodeId=d54a20635328b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Sep 28 11:48:09 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778150, encodeId=0bf71e78150e7, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Nov 29 03:48:09 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067506, encodeId=acbc106e506ba, content=很好,学到了新知识。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3475682786, createdName=ms9000001258055198, createdTime=Sat Nov 06 10:37:31 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066764, encodeId=41b51066e6424, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f1f5633705, createdName=ms1000000251410274, createdTime=Thu Nov 04 04:48:02 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066118, encodeId=dca510661180b, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/fb49ede2bc714e14abb1a1024e3f6969/ca936d1263ab48ffba726dafc70bcdb2.jpg, createdBy=92c35391508, createdName=冷小落, createdTime=Tue Nov 02 08:11:02 CST 2021, time=2021-11-02, status=1, ipAttribution=)]
    2022-09-28 achengzhao
  2. [GetPortalCommentsPageByObjectIdResponse(id=2063532, encodeId=d54a20635328b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Sep 28 11:48:09 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778150, encodeId=0bf71e78150e7, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Nov 29 03:48:09 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067506, encodeId=acbc106e506ba, content=很好,学到了新知识。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3475682786, createdName=ms9000001258055198, createdTime=Sat Nov 06 10:37:31 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066764, encodeId=41b51066e6424, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f1f5633705, createdName=ms1000000251410274, createdTime=Thu Nov 04 04:48:02 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066118, encodeId=dca510661180b, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/fb49ede2bc714e14abb1a1024e3f6969/ca936d1263ab48ffba726dafc70bcdb2.jpg, createdBy=92c35391508, createdName=冷小落, createdTime=Tue Nov 02 08:11:02 CST 2021, time=2021-11-02, status=1, ipAttribution=)]
    2021-11-29 仁者大医
  3. [GetPortalCommentsPageByObjectIdResponse(id=2063532, encodeId=d54a20635328b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Sep 28 11:48:09 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778150, encodeId=0bf71e78150e7, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Nov 29 03:48:09 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067506, encodeId=acbc106e506ba, content=很好,学到了新知识。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3475682786, createdName=ms9000001258055198, createdTime=Sat Nov 06 10:37:31 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066764, encodeId=41b51066e6424, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f1f5633705, createdName=ms1000000251410274, createdTime=Thu Nov 04 04:48:02 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066118, encodeId=dca510661180b, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/fb49ede2bc714e14abb1a1024e3f6969/ca936d1263ab48ffba726dafc70bcdb2.jpg, createdBy=92c35391508, createdName=冷小落, createdTime=Tue Nov 02 08:11:02 CST 2021, time=2021-11-02, status=1, ipAttribution=)]
    2021-11-06 ms9000001258055198

    很好,学到了新知识。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2063532, encodeId=d54a20635328b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Sep 28 11:48:09 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778150, encodeId=0bf71e78150e7, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Nov 29 03:48:09 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067506, encodeId=acbc106e506ba, content=很好,学到了新知识。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3475682786, createdName=ms9000001258055198, createdTime=Sat Nov 06 10:37:31 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066764, encodeId=41b51066e6424, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f1f5633705, createdName=ms1000000251410274, createdTime=Thu Nov 04 04:48:02 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066118, encodeId=dca510661180b, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/fb49ede2bc714e14abb1a1024e3f6969/ca936d1263ab48ffba726dafc70bcdb2.jpg, createdBy=92c35391508, createdName=冷小落, createdTime=Tue Nov 02 08:11:02 CST 2021, time=2021-11-02, status=1, ipAttribution=)]
    2021-11-04 ms1000000251410274

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2063532, encodeId=d54a20635328b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Sep 28 11:48:09 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778150, encodeId=0bf71e78150e7, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Nov 29 03:48:09 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067506, encodeId=acbc106e506ba, content=很好,学到了新知识。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3475682786, createdName=ms9000001258055198, createdTime=Sat Nov 06 10:37:31 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066764, encodeId=41b51066e6424, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f1f5633705, createdName=ms1000000251410274, createdTime=Thu Nov 04 04:48:02 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066118, encodeId=dca510661180b, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/fb49ede2bc714e14abb1a1024e3f6969/ca936d1263ab48ffba726dafc70bcdb2.jpg, createdBy=92c35391508, createdName=冷小落, createdTime=Tue Nov 02 08:11:02 CST 2021, time=2021-11-02, status=1, ipAttribution=)]
    2021-11-02 冷小落

    已学习

    0

相关资讯

超5万中国人数据:碘盐吃多了,真的会增加甲状腺结节和甲状腺癌风险!

过量摄入碘盐会增加甲状腺结节和甲状腺癌的风险,与此同时每日碘盐摄入量也可作为甲状腺结节和甲状腺癌诊断的重要参考指标!

Laryngoscope:甲状腺术后的疤痕管理策略,哪项更优?

甲状腺术后的疤痕位于高度敏感和可见的解剖位置,其对外观的影响已成为患者术后满意度的最重要因素之一。近日,发表于Laryngoscope的一项目前瞻性随机试验比较了应用不同方案时的疤痕质量,并最终旨在找

JCEM:接受甲状腺切除术的甲状腺癌患者心血管结局

DTC患者发生房颤、CVD、心率加快和左心室质量增重的风险增加。

Br J Cancer:安罗替尼通过靶向EGFR抑制未分化甲状腺癌的血管生成作用

甲状腺癌是一种最普遍的内分泌恶性肿瘤,其发病率逐年升高。

JAMA子刊:50万人数据显示,放射性碘治疗并不一定会增加甲状腺癌的风险!

甲状腺功能亢进症是甲状腺毒症的一种形式,是以组织甲状腺激素水平过高为特征的临床状态。

Int J Cancer:甲状腺癌及其相关影响因素

甲状腺癌(TC)是最常见的内分泌恶性肿瘤之一,其发病率和死亡率在世界范围内呈上升趋势。甲状腺癌在男性中排名第九,在女性中排名第五。甲状腺癌在女性中的发病率是男性的三倍。